Effects of neoadjuvant VEGF-TKI treatment on surgery for renal cell carcinoma: A systematic review and meta-analysis

被引:2
|
作者
Zhu, Meikai [1 ]
Liu, Zhifeng [2 ]
Zhou, Yongheng [1 ]
Jiang, Zhiwen [1 ]
Chen, Shouzhen [1 ]
Wang, Wenfu [1 ]
Shi, Benkang [1 ]
Zhu, Yaofeng [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Urol, 107 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China
[2] Taian City Cent Hosp, Dept Urol, Tai An 271000, Shandong, Peoples R China
关键词
neoadjuvant therapy; targeted therapy; renal cell carcinoma; surgical treatment; nephrectomy; TARGETED MOLECULAR THERAPIES; VENA-CAVA THROMBECTOMY; PARTIAL NEPHRECTOMY; TUMOR THROMBUS; SUNITINIB; SORAFENIB; AXITINIB; CANCER; TRIAL;
D O I
10.3892/ol.2024.14295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the effects of neoadjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) treatment on surgery in patients with renal cell carcinoma (RCC), sources from Embase, PubMed and the Cochrane Library databases collected from inception to December, 2022 were used for analysis in the present study, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data regarding surgical outcomes were collected. The pooled effect sizes were calculated in terms of the risk ratio (RR)/standard mean difference (SMD) with 95% confidence intervals (CIs) using the random-effects model. Subgroup and sensitivity analyses were used to explore the source of heterogeneity within the data. In total, 9 identified articles involving 829 patients (336 in the neoadjuvant + surgery group; 493 in the surgery group) were included in the present study, according to the criteria. The results demonstrated that there were no significant differences in blood loss (SMD=-0.11; 95% CI, -0.63-0.41; P=0.68), postoperative length of hospital stay or total length of hospital stay (SMD=0.23; 95% CI, -0.55-1.01; P=0.57) or complications (RR=1.16; 95% CI, 0.80-1.67; P=0.44) between the two groups. However, neoadjuvant therapy reduced the operation time (SMD=-0.67; 95% CI, -1.25- -0.09; P=0.02) and resulted in a greater proportion of patients choosing partial nephrectomy (RR=1.84; 95% CI, 1.47-2.31; P<0.00001). In the subgroup analysis, the blood loss was significantly lower in patients with RCC with inferior vena cava tumor thrombus in the neoadjuvant group (SMD=-1.10; 95% CI, -1.82- -0.38; P=0.003). In conclusion, the results of the present study indicated that neoadjuvant VEGF-TKI treatment in patients with RCC shortened operation time, decreased blood loss and did not cause an increase in perioperative complications. In addition, this treatment modality may encourage patients to opt for partial nephrectomy to preserve renal function.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis
    Wang, Hongfei
    Xu, Yuanyuan
    Shi, Jingpu
    Gao, Xinghua
    Geng, Long
    PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2015, 31 (01) : 44 - 53
  • [32] Trans-arterial embolization of renal cell carcinoma: a systematic review and meta-analysis
    Bryan Wright
    Bradley S. Johnson
    Matt Vassar
    Ava Saidian
    Soroush Rais-Bahrami
    Andrew J. Gunn
    Abdominal Radiology, 2022, 47 : 2238 - 2243
  • [33] Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
    Tang, Xiaoyi
    Liu, Ting
    Zang, Xuefeng
    Liu, Hao
    Wang, Danhong
    Chen, Hu
    Zhang, Bin
    PLOS ONE, 2013, 8 (05):
  • [34] Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
    Zhang, Siqi
    Xu, Xiaohua
    Chen, Jiaqi
    Zhang, Zhiping
    Liu, Feng
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [35] Is cytoreductive nephrectomy necessary for metastatic renal cell carcinoma: a systematic review and meta-analysis
    Luo, Xiaojin
    Yi, Meilian
    Hui, Qun
    Yin, Weihua
    Han, Dali
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (06): : 7029 - 7037
  • [36] Prognostic nutritional index and prognosis in renal cell carcinoma: A systematic review and meta-analysis
    Kim, Sun Il
    Kim, Se Joong
    Kim, Seong Jang
    Cho, Dae Sung
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 623 - 630
  • [37] Circular RNAs as Prognostic Biomarkers in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
    Liao, Dan
    Lin, Qiu
    Xiao, Huan
    Zhang, Fenglian
    Han, Qin
    FRONTIERS IN GENETICS, 2022, 13
  • [38] Sarcopenia predicts prognosis of patients with renal cell carcinoma: A systematic review and meta-analysis
    Hu, Xu
    Liao, Du-Wu
    Yang, Zhi-Qiang
    Yang, Wei-Xiao
    Xiong, San-Chao
    Li, Xiang
    INTERNATIONAL BRAZ J UROL, 2020, 46 (05): : 705 - 715
  • [39] COMBINATION THERAPY FOR METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Alam, Muhammad
    Gautam, Shiva
    Kumar, Jatinder
    Tanneru, Karthik
    Norez, Daniel
    Koochekpour, Shahriar
    Nguyen, Sabine
    Ganapathi, Hariharan Palayapalayam
    Bandyk, Mark
    Costa, Joseph
    Marino, Robert
    Balaji, K. C.
    JOURNAL OF UROLOGY, 2020, 203 : E202 - E202
  • [40] MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis
    Gu, Liangyou
    Li, Hongzhao
    Chen, Luyao
    Ma, Xin
    Gao, Yu
    Li, Xintao
    Zhang, Yu
    Fan, Yang
    Zhang, Xu
    ONCOTARGET, 2015, 6 (32) : 32545 - 32560